<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00311402</url>
  </required_header>
  <id_info>
    <org_study_id>9.178</org_study_id>
    <nct_id>NCT00311402</nct_id>
  </id_info>
  <brief_title>JASAP: Japanese Aggrenox Stroke Prevention vs. Aspirin Programme</brief_title>
  <official_title>JASAP: Japanese Aggrenox Stroke Prevention vs. Aspirin Programme, Phase III Study to Compare the Preventive Effect of Recurrent Brain Infarction and Safety of Aggrenox (Combination Drug Containing Sustained-release Dipyridamole 200 mg/Acetylsalicylic Acid 25 mg) Twice Daily vs. Acetylsalicylic Acid 81 mg Once Daily</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Phase III study to compare the preventive effect of recurrent brain infarction and safety of
      Aggrenox (combination drug containing sustained-release dipyridamole 200 mg/acetylsalicylic
      acid 25 mg) twice daily vs. acetylsalicylic acid 81 mg once daily
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With First Recurrent Cerebral Infarction (Fatal or Non-fatal)</measure>
    <time_frame>Up to 124 weeks</time_frame>
    <description>All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Brain (Cerebral) Haemorrhage</measure>
    <time_frame>Up to 124 weeks</time_frame>
    <description>All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Subarachnoid Haemorrhage</measure>
    <time_frame>Up to 124 weeks</time_frame>
    <description>All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Transient Ischemic Attack (TIA)</measure>
    <time_frame>Up to 124 weeks</time_frame>
    <description>All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Acute Coronary Syndrome (ACS)</measure>
    <time_frame>Up to 124 weeks</time_frame>
    <description>ACS contains acute myocardial infarction (MI), unstable angina and sudden cardiac death. All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Other Vascular Events</measure>
    <time_frame>Up to 124 weeks</time_frame>
    <description>This endpoints were defined as pulmonary embolism, retinal vascular disorder, deep vein thrombosis, peripheral artery obstruction and vascular intervention. All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Ischemic Vascular Event Composite Endpoint</measure>
    <time_frame>Up to 124 weeks</time_frame>
    <description>This is a composite endpoint of cerebral infarction, transient ischemic attack (TIA), acute myocardial infarction (MI), unstable angina and sudden death attributable to thromboembolism. All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1295</enrollment>
  <condition>Cerebrovascular Accident</condition>
  <arm_group>
    <arm_group_label>Aggrenox Capsule</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Acetylsalicylic Acid (ASA) 81 mg Tablet</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aggrenox capsule</intervention_name>
    <description>extended-release dipyridamole 200 mg plus ASA 50 mg in a capsule, 2 capsules twice daily</description>
    <arm_group_label>Aggrenox Capsule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Acetylsalicylic Acid (ASA)</intervention_name>
    <description>Acetylsalicylic Acid (ASA) 81 mg, 1 tablet once daily</description>
    <arm_group_label>Acetylsalicylic Acid (ASA) 81 mg Tablet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients with a diagnosis of cerebral infarction (excluding cardiogenic cerebral embolism)
        who meet the diagnostic criteria based on the National Institute of Neurological Disorders
        and Stroke (NINDS) ad hoc committee's classification of cerebrovascular disease III.

          1. Patients who have had an onset of cerebral infarction, the time of which is known,
             between 1 week and 6 months before the time of enrolment (including first and
             recurrent cerebral infarctions)

          2. Patients who are 50 years or older

          3. Patients whose neurological signs and symptoms are considered to be stable by the
             investigator or sub-investigator

          4. Patients with a finding corresponding to the responsible focus confirmed by head X-ray
             computerised tomography (CT) or magnetic resonance imaging (MRI)

          5. Patients who have at least two of the following risk factors:

               -  diabetes

               -  hypertension (systolic blood pressure is 140 mmHg or higher or diastolic blood
                  pressure is 90 mmHg or higher) or under treatment of hypertension

               -  smoker (at the time of onset of cerebral infarction)

               -  obesity (Body mass index (BMI) is more than 25 kg/m2)

               -  previous vascular disease (stroke, acute myocardial infarction or peripheral
                  arterial disease before the onset of cerebral infarction)

               -  end-organ damage (retinopathy, left ventricular hypertrophy (LVH) or
                  microalbuminuria)

               -  hyperlipidaemia

        Exclusion Criteria:

          1. Patients with a diagnosis of brain disorders with a bleeding risk such as brain
             haemorrhage, subarachnoid haemorrhage, cerebral arteriovenous (AV) malformation,
             cerebral AV aneurysms and brain tumours

          2. Patients with complications of cardiac disorders (atrial fibrillation, mitral valve
             stenosis, severe cardiac valve disorders) that may provide an embolic source for
             cerebral embolism

          3. Patients having had acute coronary syndromes (acute myocardial infarction, unstable
             angina) within 6 months after enrolment in this study

          4. Patient with hypersensitivity to dipyridamole preparations

          5. Patients with a history of drug allergy to acetylsalicylic acid (ASA) or aspirin
             asthma

          6. Patients with a history of peptic ulcer

          7. Patients having undergone arterial reconstruction after development of cerebral
             infarction

          8. Patients with very severe impairment (4 or 5 on Modified Rankin Scale)

          9. Patients with bleeding or bleeding tendencies (haemophilia, haemorrhage urinary tract,
             vitreous haemorrhage, etc.)

         10. Patients with severe hypertension (systolic blood pressure is 180 mmHg or higher or
             diastolic blood pressure is 110 mmHg or higher)

         11. Patients with complications such as serious cardiac, renal and hepatic disorders

         12. Patients with a malignant tumour or having had a tumour treatment in the past 5 years

         13. Women who are or may be pregnant or lactating women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>9.178.060 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Adachi-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Adumino, Nagano</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.032 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Akashi, Hyogo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.074 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Akashi, Hyogo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.062 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ako, Hyogo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.064 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aoba-ku, Yokohama, Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.097 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aoi-ku, Shizuoka, Shizuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.056 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Asahi, Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.067 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Asahikawa, Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.117 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Asahikawa, Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.166 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Atsugi, Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.089 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bunkyo-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.054 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chitose, Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.133 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chuo-ku, Chiba, Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.030 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chuo-ku, Kobe, Hyogo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.077 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chuo-ku, Sapporo, Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chuo-Ku, Sappro, Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.119 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chuo-ku, Sappro, Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.161 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Daito, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.112 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fuchu, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.098 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fujieda, Shizuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.046 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fukaya, Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.145 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fukui, Fukui</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.099 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fukuroi, Shizuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.165 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Funabashi, Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.072 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fushimi-ku, Kyoto, Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.081 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gifu, Gifu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.024 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Habikino, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.136 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hachioji, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.082 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hakodate, Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.118 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hakodate, Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.052 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamada, Shimane</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.138 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hashima-gun, Gifu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.169 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hidaka, Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Higashi-ku, Sappro, Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.026 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Higashi-osaka, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.163 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Higashidakawa-gun, Yamagata</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.120 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Higashimatsushima, Miyagi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.028 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Higashinari-ku, Osaka, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.140 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Higashiosaka, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.122 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Higashisonogi-gun, Nagasaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Higashiyodogawa-ku, Osaka, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.093 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Himeji, Hyogo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.153 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hitachi, Ibaraki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hitachinaka, Ibaraki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.079 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ibusuki, Kagoshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.143 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ichikawa, Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Iida, Nagano</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.129 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Inashiki-gun, Ibaraki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Isesaki, Gunma</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.045 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Isesaki, Gunma</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.031 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Itami, Hyogo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.135 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Iwanuma, Miyagi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.104 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Iwata, Shizuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.095 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Izuka, Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.080 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Izumisano, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.139 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Izumo, Shimane</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.113 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Izunokuni, Shizuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.115 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kahoku-gun, Ishikawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.147 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kameda-gun, Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.092 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kamigyo-ku, Kyoto, Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kasama, Ibaraki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.035 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kasuga, Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.037 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kasuga, Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.051 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kawachinagano, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.086 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kisarazu, Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.162 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kishiwada, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.102 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kita-ku, Nagoya, Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.023 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kita-ku, Osaka, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.127 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kita-ku, Osaka, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kita-ku, Sappro, Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.154 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kitami, Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.155 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kitami, Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.069 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kiyose, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.070 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kiyose, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.121 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kochi, Kochi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.141 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kochi, Kochi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.061 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Koriyama, Fukushima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.085 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Koriyama, Fukushima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.075 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Koshi, Kumamoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.107 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kurashiki, Okayama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.063 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kushiro, Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.083 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kushiro, Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.126 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kushiro, Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.150 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Marugame, Kagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.164 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Matsudo, Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Matsumoto, Nagano</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.130 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Meguro-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.057 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Meito-ku, Nagoya, Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Midori-ku, Yokohama, Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.043 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Minami-ku, Hiroshima, Hiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.068 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Miyagino-ku, Sendai, Miyagi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.116 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Miyazaki, Miyazaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.142 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moriguchi, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.078 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Morioka, Iwate</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.084 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Morioka, Iwate</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moriya, Ibaraki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.149 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moriya, Ibaraki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.071 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Musashimurayama, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Musashino, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.100 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Naka-ku, Hamamatsu, Shizuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.110 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Naka-ku, Hamamatsu, Shizuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Naka-ku, Nagoya, Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.053 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nakagawa-ku, Nagoya, Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.132 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nakagawa-ku, Nagoya, Nagoya</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.124 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Namegata, Ibaraki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.158 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nanao, Ishikawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.029 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nishi-yodogawa-ku, Osaka, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.096 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nishisonogi-gun, Nagasaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.087 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Noda, Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.058 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Obu, Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.034 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ohnojo, Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.157 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Okayama, Okayama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.167 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Okinawa, Okinawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.137 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sagamihara, Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.027 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sakai, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.073 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sakai, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saku, Nagano</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.160 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sapporo, Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.041 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Setagaya-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.088 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shibuya-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.022 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shimogyo-ku, Kyoto, Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.076 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shimotsuke, Tochigi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.055 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shiroishi, Miyagi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.111 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Simizu-ku, Shizuoka, Shizuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.151 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Suminoe-ku, Osaka, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.156 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Susono, Shizuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Suwa, Nagano</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.039 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Takasaki, Gunma</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.146 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Takatsuki, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.144 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Takayama, Gifu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Takikawa, Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.040 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tatebayashi, Gunma</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.066 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Teine-ku, Sapporo, Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.134 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tenri, Nara</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.159 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tonami, Toyama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toride, Ibaraki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.047 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toyama, Toyama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.090 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toyohashi, Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.131 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toyota, Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tsuchiura, Ibaraki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ueda, Nagano</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.091 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Uji, Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.050 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ukyo-ku, Kyoto, Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.106 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Urayasu, Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.148 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wakayama, Wakayama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.114 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wko, Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.152 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Yaizu, Shizuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.125 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Yamashina, Kyoto, Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.108 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Yanai, Yamaguchi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9.178.103 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Yao, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 28, 2006</study_first_submitted>
  <study_first_submitted_qc>April 4, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2006</study_first_posted>
  <results_first_submitted>February 16, 2010</results_first_submitted>
  <results_first_submitted_qc>February 16, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 11, 2010</results_first_posted>
  <last_update_submitted>January 21, 2014</last_update_submitted>
  <last_update_submitted_qc>January 21, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 14, 2014</last_update_posted>
  <responsible_party>
    <name_title>Boehringer Ingelheim, Study Chair</name_title>
    <organization>Boehringer Ingelheim</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Dipyridamole</mesh_term>
    <mesh_term>Aspirin, Dipyridamole Drug Combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patient recruitment initiated from June 2006 and completed in December 2007.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Aggrenox Capsule</title>
          <description>Aggrenox (extended-release dipyridamole 200 mg plus ASA 50 mg in a capsule), 2 capsules twice daily</description>
        </group>
        <group group_id="P2">
          <title>Acetylsalicylic Acid (ASA) 81 mg Tablet</title>
          <description>ASA 81 mg, 1 tablet once daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="655"/>
                <participants group_id="P2" count="639"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="445"/>
                <participants group_id="P2" count="462"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="210"/>
                <participants group_id="P2" count="177"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="118"/>
                <participants group_id="P2" count="105"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="42"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>IRB's rejection etc.</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Aggrenox Capsule</title>
          <description>Aggrenox (extended-release dipyridamole 200 mg plus ASA 50 mg in a capsule), 2 capsules twice daily</description>
        </group>
        <group group_id="B2">
          <title>Acetylsalicylic Acid (ASA) 81 mg Tablet</title>
          <description>ASA 81 mg, 1 tablet once daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="655"/>
            <count group_id="B2" value="639"/>
            <count group_id="B3" value="1294"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.2" spread="8.1"/>
                    <measurement group_id="B2" value="66.0" spread="8.6"/>
                    <measurement group_id="B3" value="66.1" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="183"/>
                    <measurement group_id="B2" value="186"/>
                    <measurement group_id="B3" value="369"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="472"/>
                    <measurement group_id="B2" value="453"/>
                    <measurement group_id="B3" value="925"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With First Recurrent Cerebral Infarction (Fatal or Non-fatal)</title>
        <description>All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner.</description>
        <time_frame>Up to 124 weeks</time_frame>
        <population>All outcomes and efficacy endpoints were analysed on the basis of the full analysis set (FAS). FAS population excluded that 1) patients who did not meet inclusion criteria, 2) patients who had never taken the investigational products, and 3) patients who had no data after drug administration.</population>
        <group_list>
          <group group_id="O1">
            <title>Aggrenox Capsule</title>
            <description>Aggrenox (extended-release dipyridamole 200 mg plus ASA 50 mg in a capsule), 2 capsules twice daily</description>
          </group>
          <group group_id="O2">
            <title>Acetylsalicylic Acid (ASA) 81 mg Tablet</title>
            <description>ASA 81 mg, 1 tablet once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With First Recurrent Cerebral Infarction (Fatal or Non-fatal)</title>
          <description>All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner.</description>
          <population>All outcomes and efficacy endpoints were analysed on the basis of the full analysis set (FAS). FAS population excluded that 1) patients who did not meet inclusion criteria, 2) patients who had never taken the investigational products, and 3) patients who had no data after drug administration.</population>
          <units>patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="652"/>
                <count group_id="O2" value="639"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-event rate was calculated by using the Kaplan-Meier method and the comparison of groups was made by using the Cox proportional hazard regression model.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The non-event rates after 1 year in the Aggrenox group and ASA group are estimated at 94.0% and 91.5%, respectively. The non-inferiority margin was set to 2%. Under these conditions, 500 patients per group were supposed to be enough to detect the non-inferiority of Aggrenox with over 80% power.</non_inferiority_desc>
            <p_value>0.097</p_value>
            <method>Regression, Cox</method>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>1.47</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.93</ci_lower_limit>
            <ci_upper_limit>2.31</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Brain (Cerebral) Haemorrhage</title>
        <description>All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner.</description>
        <time_frame>Up to 124 weeks</time_frame>
        <population>All outcomes and efficacy endpoints were analysed on the basis of the full analysis set (FAS). FAS population excluded that 1) patients who did not meet inclusion criteria, 2) patients who had never taken the investigational products, and 3) patients who had no data after drug administration.</population>
        <group_list>
          <group group_id="O1">
            <title>Aggrenox Capsule</title>
            <description>Aggrenox (extended-release dipyridamole 200 mg plus ASA 50 mg in a capsule), 2 capsules twice daily</description>
          </group>
          <group group_id="O2">
            <title>Acetylsalicylic Acid (ASA) 81 mg Tablet</title>
            <description>ASA 81 mg, 1 tablet once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Brain (Cerebral) Haemorrhage</title>
          <description>All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner.</description>
          <population>All outcomes and efficacy endpoints were analysed on the basis of the full analysis set (FAS). FAS population excluded that 1) patients who did not meet inclusion criteria, 2) patients who had never taken the investigational products, and 3) patients who had no data after drug administration.</population>
          <units>patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="652"/>
                <count group_id="O2" value="639"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-event rate was calculated by using the Kaplan-Meier method and the comparison of groups was made by using the Cox proportional hazard regression model.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.223</p_value>
            <method>Regression, Cox</method>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>1.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>4.54</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Subarachnoid Haemorrhage</title>
        <description>All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner.</description>
        <time_frame>Up to 124 weeks</time_frame>
        <population>All outcomes and efficacy endpoints were analysed on the basis of the full analysis set (FAS). FAS population excluded that 1) patients who did not meet inclusion criteria, 2) patients who had never taken the investigational products, and 3) patients who had no data after drug administration.</population>
        <group_list>
          <group group_id="O1">
            <title>Aggrenox Capsule</title>
            <description>Aggrenox (extended-release dipyridamole 200 mg plus ASA 50 mg in a capsule), 2 capsules twice daily</description>
          </group>
          <group group_id="O2">
            <title>Acetylsalicylic Acid (ASA) 81 mg Tablet</title>
            <description>ASA 81 mg, 1 tablet once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Subarachnoid Haemorrhage</title>
          <description>All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner.</description>
          <population>All outcomes and efficacy endpoints were analysed on the basis of the full analysis set (FAS). FAS population excluded that 1) patients who did not meet inclusion criteria, 2) patients who had never taken the investigational products, and 3) patients who had no data after drug administration.</population>
          <units>patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="652"/>
                <count group_id="O2" value="639"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-event rate was calculated by using the Kaplan-Meier method and the comparison of groups was made by using the Cox proportional hazard regression model.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.998</p_value>
            <method>Regression, Cox</method>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>0</ci_lower_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Transient Ischemic Attack (TIA)</title>
        <description>All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner.</description>
        <time_frame>Up to 124 weeks</time_frame>
        <population>All outcomes and efficacy endpoints were analysed on the basis of the full analysis set (FAS). FAS population excluded that 1) patients who did not meet inclusion criteria, 2) patients who had never taken the investigational products, and 3) patients who had no data after drug administration.</population>
        <group_list>
          <group group_id="O1">
            <title>Aggrenox Capsule</title>
            <description>Aggrenox (extended-release dipyridamole 200 mg plus ASA 50 mg in a capsule), 2 capsules twice daily</description>
          </group>
          <group group_id="O2">
            <title>Acetylsalicylic Acid (ASA) 81 mg Tablet</title>
            <description>ASA 81 mg, 1 tablet once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Transient Ischemic Attack (TIA)</title>
          <description>All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner.</description>
          <population>All outcomes and efficacy endpoints were analysed on the basis of the full analysis set (FAS). FAS population excluded that 1) patients who did not meet inclusion criteria, 2) patients who had never taken the investigational products, and 3) patients who had no data after drug administration.</population>
          <units>patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="652"/>
                <count group_id="O2" value="639"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-event rate was calculated by using the Kaplan-Meier method and the comparison of groups was made by using the Cox proportional hazard regression model.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.977</p_value>
            <method>Regression, Cox</method>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>1.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.21</ci_lower_limit>
            <ci_upper_limit>5.07</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Acute Coronary Syndrome (ACS)</title>
        <description>ACS contains acute myocardial infarction (MI), unstable angina and sudden cardiac death. All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner.</description>
        <time_frame>Up to 124 weeks</time_frame>
        <population>All outcomes and efficacy endpoints were analysed on the basis of the full analysis set (FAS). FAS population excluded that 1) patients who did not meet inclusion criteria, 2) patients who had never taken the investigational products, and 3) patients who had no data after drug administration.</population>
        <group_list>
          <group group_id="O1">
            <title>Aggrenox Capsule</title>
            <description>Aggrenox (extended-release dipyridamole 200 mg plus ASA 50 mg in a capsule), 2 capsules twice daily</description>
          </group>
          <group group_id="O2">
            <title>Acetylsalicylic Acid (ASA) 81 mg Tablet</title>
            <description>ASA 81 mg, 1 tablet once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Acute Coronary Syndrome (ACS)</title>
          <description>ACS contains acute myocardial infarction (MI), unstable angina and sudden cardiac death. All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner.</description>
          <population>All outcomes and efficacy endpoints were analysed on the basis of the full analysis set (FAS). FAS population excluded that 1) patients who did not meet inclusion criteria, 2) patients who had never taken the investigational products, and 3) patients who had no data after drug administration.</population>
          <units>patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="652"/>
                <count group_id="O2" value="639"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-event rate was calculated by using the Kaplan-Meier method and the comparison of groups was made by using the Cox proportional hazard regression model.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.192</p_value>
            <method>Regression, Cox</method>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.26</ci_lower_limit>
            <ci_upper_limit>1.31</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Other Vascular Events</title>
        <description>This endpoints were defined as pulmonary embolism, retinal vascular disorder, deep vein thrombosis, peripheral artery obstruction and vascular intervention. All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner.</description>
        <time_frame>Up to 124 weeks</time_frame>
        <population>All outcomes and efficacy endpoints were analysed on the basis of the full analysis set (FAS). FAS population excluded that 1) patients who did not meet inclusion criteria, 2) patients who had never taken the investigational products, and 3) patients who had no data after drug administration.</population>
        <group_list>
          <group group_id="O1">
            <title>Aggrenox Capsule</title>
            <description>Aggrenox (extended-release dipyridamole 200 mg plus ASA 50 mg in a capsule), 2 capsules twice daily</description>
          </group>
          <group group_id="O2">
            <title>Acetylsalicylic Acid (ASA) 81 mg Tablet</title>
            <description>ASA 81 mg, 1 tablet once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Other Vascular Events</title>
          <description>This endpoints were defined as pulmonary embolism, retinal vascular disorder, deep vein thrombosis, peripheral artery obstruction and vascular intervention. All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner.</description>
          <population>All outcomes and efficacy endpoints were analysed on the basis of the full analysis set (FAS). FAS population excluded that 1) patients who did not meet inclusion criteria, 2) patients who had never taken the investigational products, and 3) patients who had no data after drug administration.</population>
          <units>patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="652"/>
                <count group_id="O2" value="639"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-event rate was calculated by using the Kaplan-Meier method and the comparison of groups was made by using the Cox proportional hazard regression model.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.215</p_value>
            <method>Regression, Cox</method>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>1.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.69</ci_lower_limit>
            <ci_upper_limit>5.07</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Ischemic Vascular Event Composite Endpoint</title>
        <description>This is a composite endpoint of cerebral infarction, transient ischemic attack (TIA), acute myocardial infarction (MI), unstable angina and sudden death attributable to thromboembolism. All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner.</description>
        <time_frame>Up to 124 weeks</time_frame>
        <population>All outcomes and efficacy endpoints were analysed on the basis of the full analysis set (FAS). FAS population excluded that 1) patients who did not meet inclusion criteria, 2) patients who had never taken the investigational products, and 3) patients who had no data after drug administration.</population>
        <group_list>
          <group group_id="O1">
            <title>Aggrenox Capsule</title>
            <description>Aggrenox (extended-release dipyridamole 200 mg plus ASA 50 mg in a capsule), 2 capsules twice daily</description>
          </group>
          <group group_id="O2">
            <title>Acetylsalicylic Acid (ASA) 81 mg Tablet</title>
            <description>ASA 81 mg, 1 tablet once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Ischemic Vascular Event Composite Endpoint</title>
          <description>This is a composite endpoint of cerebral infarction, transient ischemic attack (TIA), acute myocardial infarction (MI), unstable angina and sudden death attributable to thromboembolism. All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner.</description>
          <population>All outcomes and efficacy endpoints were analysed on the basis of the full analysis set (FAS). FAS population excluded that 1) patients who did not meet inclusion criteria, 2) patients who had never taken the investigational products, and 3) patients who had no data after drug administration.</population>
          <units>patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="652"/>
                <count group_id="O2" value="639"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-event rate was calculated by using the Kaplan-Meier method and the comparison of groups was made by using the Cox proportional hazard regression model.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.443</p_value>
            <method>Regression, Cox</method>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>1.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>1.69</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Number of Patients With Stroke</title>
        <description>This is a composite endpoint of cerebral infarction, brain (cerebral) hemorrhage and subarachnoid haemorrhage. All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner.</description>
        <time_frame>Up to 124 weeks</time_frame>
        <population>All outcomes and efficacy endpoints were analysed on the basis of the full analysis set (FAS). FAS population excluded that 1) patients who did not meet inclusion criteria, 2) patients who had never taken the investigational products, and 3) patients who had no data after drug administration.</population>
        <group_list>
          <group group_id="O1">
            <title>Aggrenox Capsule</title>
            <description>Aggrenox (extended-release dipyridamole 200 mg plus ASA 50 mg in a capsule), 2 capsules twice daily</description>
          </group>
          <group group_id="O2">
            <title>Acetylsalicylic Acid (ASA) 81 mg Tablet</title>
            <description>ASA 81 mg, 1 tablet once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Stroke</title>
          <description>This is a composite endpoint of cerebral infarction, brain (cerebral) hemorrhage and subarachnoid haemorrhage. All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner.</description>
          <population>All outcomes and efficacy endpoints were analysed on the basis of the full analysis set (FAS). FAS population excluded that 1) patients who did not meet inclusion criteria, 2) patients who had never taken the investigational products, and 3) patients who had no data after drug administration.</population>
          <units>patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="652"/>
                <count group_id="O2" value="639"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-event rate was calculated by using the Kaplan-Meier method and the comparison of groups was made by using the Cox proportional hazard regression model.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.043</p_value>
            <method>Regression, Cox</method>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>1.52</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.01</ci_lower_limit>
            <ci_upper_limit>2.29</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Number of Patients With Intracranial Haemorrhage</title>
        <description>All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner.</description>
        <time_frame>Up to 124 weeks</time_frame>
        <population>All outcomes and efficacy endpoints were analysed on the basis of the full analysis set (FAS). FAS population excluded that 1) patients who did not meet inclusion criteria, 2) patients who had never taken the investigational products, and 3) patients who had no data after drug administration.</population>
        <group_list>
          <group group_id="O1">
            <title>Aggrenox Capsule</title>
            <description>Aggrenox (extended-release dipyridamole 200 mg plus ASA 50 mg in a capsule), 2 capsules twice daily</description>
          </group>
          <group group_id="O2">
            <title>Acetylsalicylic Acid (ASA) 81 mg Tablet</title>
            <description>ASA 81 mg, 1 tablet once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Intracranial Haemorrhage</title>
          <description>All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner.</description>
          <population>All outcomes and efficacy endpoints were analysed on the basis of the full analysis set (FAS). FAS population excluded that 1) patients who did not meet inclusion criteria, 2) patients who had never taken the investigational products, and 3) patients who had no data after drug administration.</population>
          <units>patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="652"/>
                <count group_id="O2" value="639"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-event rate was calculated by using the Kaplan-Meier method and the comparison of groups was made by using the Cox proportional hazard regression model.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.919</p_value>
            <method>Regression, Cox</method>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>1.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.48</ci_lower_limit>
            <ci_upper_limit>2.25</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Number of Patients With Composite Endpoint of Stroke or Major Bleeding</title>
        <description>This is a composite endpoint of cerebral infarction, brain (cerebral) hemorrhage, subarachnoid haemorrhage and major bleeding. All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner.</description>
        <time_frame>Up to 124 weeks</time_frame>
        <population>All outcomes and efficacy endpoints were analysed on the basis of the full analysis set (FAS). FAS population excluded that 1) patients who did not meet inclusion criteria, 2) patients who had never taken the investigational products, and 3) patients who had no data after drug administration.</population>
        <group_list>
          <group group_id="O1">
            <title>Aggrenox Capsule</title>
            <description>Aggrenox (extended-release dipyridamole 200 mg plus ASA 50 mg in a capsule), 2 capsules twice daily</description>
          </group>
          <group group_id="O2">
            <title>Acetylsalicylic Acid (ASA) 81 mg Tablet</title>
            <description>ASA 81 mg, 1 tablet once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Composite Endpoint of Stroke or Major Bleeding</title>
          <description>This is a composite endpoint of cerebral infarction, brain (cerebral) hemorrhage, subarachnoid haemorrhage and major bleeding. All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner.</description>
          <population>All outcomes and efficacy endpoints were analysed on the basis of the full analysis set (FAS). FAS population excluded that 1) patients who did not meet inclusion criteria, 2) patients who had never taken the investigational products, and 3) patients who had no data after drug administration.</population>
          <units>patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="652"/>
                <count group_id="O2" value="639"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-event rate was calculated by using the Kaplan-Meier method and the comparison of groups was made by using the Cox proportional hazard regression model.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.101</p_value>
            <method>Regression, Cox</method>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>1.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.94</ci_lower_limit>
            <ci_upper_limit>1.91</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From day of first drug dose until 6 days after last dose, up to 874 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Aggrenox Capsule</title>
          <description>Aggrenox (extended-release dipyridamole 200 mg plus ASA 50 mg in a capsule), 2 capsules twice daily</description>
        </group>
        <group group_id="E2">
          <title>Acetylsalicylic Acid (ASA) 81 mg Tablet</title>
          <description>ASA 81 mg, 1 tablet once daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="178" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="167" subjects_at_risk="639"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="639"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Right ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="639"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Auricular perichondritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Vertigo labyrinthine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="639"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperadrenalism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="639"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Maculopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Eyelid ptosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Retinal artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Retinal vein occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Vitreous haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="639"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colonic polyp</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Acute abdomen</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Gastric polyps</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Gastritis atrophic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Gastritis haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Intestinal ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Mallory-Weiss syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Oesophageal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Oesophageal rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Oesophageal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Oesophagitis haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="639"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Implant site inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Oedema due to renal disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="639"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Gallbladder polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Hepatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="639"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Acute tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Bronchopulmonary aspergillosis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Peritonsillar abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Pleurisy viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="639"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage traumatic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Meniscus lesion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Blast injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Brain contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Burns first degree</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Burns second degree</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Diffuse axonal injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Fat embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Limb traumatic amputation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Neck injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Pubic rami fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Scapula fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Subdural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="639"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Prostatic specific antigen increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="639"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="639"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Cervical spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Dupuytren's contracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="639"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Hepatic neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Large intestine carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Colon adenoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Gastrointestinal stromal tumour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Intestinal adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Laryngeal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Leiomyosarcoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Malignant pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Neoplasm progression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Ovarian cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Ovarian neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Rectosigmoid cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Salivary gland neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="639"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Cerebellar haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Thalamus haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Basilar migraine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Cerebellar infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Haemorrhagic cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Hypertensive encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Mental impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Nystagmus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Putamen haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Spondylitic myelopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="639"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Anxiety disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Schizophrenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="639"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus bladder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Diabetic nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="639"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Pelvic haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="639"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Hyperventilation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="639"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia facial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="639"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Shock haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="639"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="634" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="604" subjects_at_risk="639"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="639"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="281" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="261" subjects_at_risk="639"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="639"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="639"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="293" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="187" subjects_at_risk="639"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="639"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="639"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="639"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

